{"id":"puva-8mop-uva-ifn","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxicity/erythema"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Flu-like symptoms (from interferon)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"8-methoxypsoralen (8MOP) is activated by UVA radiation to create DNA crosslinks in rapidly dividing cells, particularly effective against cutaneous T-cell lymphomas. Interferon-alpha augments this effect by enhancing natural killer cell activity and promoting differentiation of malignant T cells toward apoptosis. The combination targets both the direct cytotoxic effects of photochemotherapy and the immunomodulatory response against lymphoma cells.","oneSentence":"PUVA (psoralen + UVA phototherapy) combined with interferon-alpha works by inducing apoptosis of malignant T cells through photochemical DNA damage and enhancing immune-mediated tumor cell destruction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:24.441Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)"}]},"trialDetails":[{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01559584","phase":"NA","title":"Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT00630903","phase":"PHASE4","title":"PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides","status":"TERMINATED","sponsor":"Madrilenian Group of Cutaneous Lymphomas","startDate":"2000-01","conditions":"Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PUVA (8MOP + UVA) + IFN","genericName":"PUVA (8MOP + UVA) + IFN","companyName":"Madrilenian Group of Cutaneous Lymphomas","companyId":"madrilenian-group-of-cutaneous-lymphomas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PUVA (psoralen + UVA phototherapy) combined with interferon-alpha works by inducing apoptosis of malignant T cells through photochemical DNA damage and enhancing immune-mediated tumor cell destruction. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}